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introduction
Low-grade glioma (LGG) encompasses a diverse group of
primary, diffuse, slowly growing glial brain tumours. The
optimal management of LGG remains controversial and is
usually based on a number of clinical prognostic factors. The
decision to treat takes into account tumour size and histology,
control of symptoms (e.g. epilepsy) and age of the patient.
Treatment decisions must balance the benefits of therapy
against the potential for treatment-related complications.
clinical prognostic factors
Several investigators have tried to retrospectively identify
prognostic factors in LGG. Lote et al. [1] identified 379 patients
with LGG treated over 15 years at the Norwegian Radium
Hospital. In an univariate analysis, younger age, good WHO
performance status, the absence of neurological deficits and
absence of contrast enhancement on imaging were all found to
be associated with longer survival. In a multivariate analysis,
performance status, neurological symptoms or initial
corticosteroid dependency, contrast enhancement and age
remained statistically significant prognostic factors.
In a subsequent study, the database from the Norwegian
Radium Hospital (n = 160) was pooled with the databases
from the London (Ontario) Regional Cancer Centre (n = 179)
and the University of California at San Francisco (n = 62) [2].
Four different prognostic classes were identified using
a recursive partitioning analysis (Table 1). Younger patients
(18–40 years of age) with a good performance status (PS) (KPS
‡70%) had a median survival of >10 years; younger patients
with a poor PS (KPS <70%) and older patients (>40 years of
age) with a good PS and no contrast enhancement had
a median survival of >7 years; older patients with a good PS
and with contrast enhancement had a median survival of
<4 years; and older patients with a poor PS had a median
survival of only 12 months.
In the NCCTG trial [3] age, histology and tumour size were
the most significant predictors of overall survival. The degree of
resection did not significantly affect overall survival. Various
prognostic factors strongly affected outcome: patients <40 years
with oligodendroglioma had a 5-year survival of 82%,
compared with 32% in those >40 years with astrocytoma.
Significantly better survival was associated with
oligodendroglioma or oligo-dominant histology, small tumours
(<5 cm) and/or younger age (<40 years). When combined,
histologic subtype and age were particularly powerful
predictors of overall survival.
The EORTC developed a prognostic score based on two
large, randomized, multicentre trials with a total of >600
patients (Table 2) [4]. The first study (EORTC 22844) [5]
served to construct a model of prognostic factors, which was
validated with the data set of the subsequent trial (EORTC
22845) [6]. In a multivariate analysis, age ‡40 years, astrocytic
tumour type, tumour size >6 cm, tumour crossing the midline
and neurological deficit at diagnosis (before surgery) were
retained in the model. A score was established depending on
the number of unfavourable prognostic factors. Survival
decreased with each unfavourable factor. A favourable
(low-risk) prognostic score was defined as no more than two
of these adverse factors and was associated with a median
survival of 7.7 years (95% CI = 6.6, 9.3). The presence of
three to five prognostic factors (a high-risk prognostic score)
was associated with a median survival of 3.2 years (95%
CI = 3.0, 4.0).
radiotherapy
timing of radiotherapy
The optimal management of supratentorial LGG is unknown
and the identification of patients needing treatment is based on
prognostic factors as outlined above. Radiotherapy is able to
control symptoms in up to 80% of cases [7]. There is no
consensus on the treatment strategy for adult patients with this
tumour category. Patients above the age of 40, patients with
large unresectable tumours and patients with a neurological
deficit are considered to be at high risk of recurrence or
progression and are usually treated with radiation therapy. In
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almost all patients tumours will eventually recur or progress
over the years following diagnosis. In a previous study by the
EORTC [6, 8] an improved progression-free survival (5.3 years
compared with 3.4 years) was shown for patients treated with
immediate radiotherapy; however, no difference in overall
survival could be demonstrated. Despite a median delay of
tumour progression by 2 years with radiotherapy, the early
treatment did not prolong overall survival. The effect on quality
of life and neurocognitive function remains unclear [8]. By
deferring treatment, a considerable proportion of patients
(35%) did not require any radiotherapy at a median follow-up
of 7.8 years [8]. Although seizure control is improved after
radiotherapy, it is assumed that by deferring radiotherapy
eventual treatment-related late neurocognitive toxicity can also
be delayed.
For the Radiation Therapy Oncology Group (RTOG) study #
9802 patients were classified into favourable and unfavourable
prognostic groups [9]. Favourable patients (age <40 years
who undergo gross total resection) were simply observed in
a single-arm phase II study (Arm 1). Unfavourable patients
(age >40 or subtotal resection or biopsy) were all treated with
immediate radiotherapy (6 chemotherapy, see below). After
stratification by age, histology, KPS and presence/absence of
contrast enhancement on preoperative magnetic resonance
imaging (MRI) patients were randomized to either
radiotherapy alone (54 Gy) (Arm 2) or radiotherapy followed
by six cycles of standard dose PCV (procarbazine, lomustine
and vincristine) (Arm 3). Initial results showed a similar 5-year
progression-free survival for all three treatment arms ranging
from 42% to 60% [9]. Only half of the favourable patients
were disease-free at 5 years.
dose of radiotherapy
Another controversial issue is the radiotherapy dose. Many
radiation oncologists usually prescribe a total dose of 50–55 Gy
(1.8–2 Gy/fraction). Some retrospective single-arm studies have
suggested doses of >53 Gy being associated with a better
outcome regarding survival [3, 10] others did not [1, 11].
The optimal dose was investigated in two prospective
randomized studies. The EORTC and US Intergroup (NCCTG-
RTOG-ECOG) studies both showed no advantage in overall
survival for higher doses when comparing 45 Gy and 59.4 Gy,
and 50.4 Gy and 64.8 Gy, respectively [3, 5].
toxicity of radiotherapy
Treatment-related late toxicity is of concern, in particular in
view of the rather long survival of patients with LGG. Radiation
therapy to the brain is associated with white matter changes,
cognitive deficits and radiation necrosis. A 2-year actuarial
incidence of grade ‡3 radiation necrosis of 2.5% has been
observed in patients treated with a total dose of 50.4 Gy
compared with a 5% rate using 64.8 Gy in the randomized
Intergroup trial [3]. The effects of early versus delayed
radiotherapy on quality of life and cognitive functioning have
been analysed in small patient cohorts and did not differ
significantly in irradiated and non-irradiated patients with
LGG [12]. However, if those patients were compared with
a control group suffering from indolent haematological
malignancies without central nervous system involvement,
LGG patients had a significantly worse cognitive function. This
was confirmed in a second multi-centre study where
cognitive disability in the memory domain was significantly
worse in irradiated patients [13]. The latter was pronounced if
doses per fraction exceeding 2 Gy were applied. The tumour
itself seems to have the most deleterious effect on cognitive
function and additionally the use of antiepileptic drugs [14].
Comparing patients treated with postoperative radiotherapy
with those having undergone surgery only, a more severe
leukencephalopathy and a significantly worse cognitive
performance were seen even after correction for confounding
risk factors as histological grading, epilepsy, tumour location,
etc [15]. Evaluating cognitive function only by the Mini-Mental
State Examination (MMSE) may underestimate the cognitive
deficit [16]. Prospectively evaluated cognitive function with
an extensive battery of psychometric tests at baseline (before
radiotherapy) and at 18-month intervals for as long as 5 years
after completing radiotherapy in a small subgroup of patients
from the Intergroup study comparing two different
radiotherapy dose schedules (50.4 Gy versus 64.8 Gy) are
reported as being stable after radiotherapy during 3 years of
follow-up [17]. Interestingly, the neuropsychological baseline
test scores were below average compared with age-specific
norms [17].
Patients who received 54 Gy compared with 45 Gy in the
EORTC 22844 trial tended to report lower levels of functioning
concerning quality of life [13]. This was especially true for
fatigue, insomnia and emotional functioning. Taken together,
the studies in which adverse effects of radiotherapy were
Table 1. Prognostic score according to Bauman et al. [2]
Prognostic classes Median overall survival (months)
I 12
II 46
III 87
IV 128
Table 2. Prognostic score and risk groups of EORTC 22844 and 22845 [4]
EORTC 22844 EORTC 22845
Construction set (n = 281) Validation set (n = 253)
Score Risk group No. Median survival (year) (95% CI) No. Median survival (year) (95% CI)
0–2 Low 200 7.7 (6.5–9.2) 195 7.8 (6.7–8.9)
3–5 High 81 3.2 (2.9–3.9) 58 3.6 (2.8–4.6)
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observed had used higher dose prescriptions and larger
treatment fields [15, 18]. In studies which use modern standards
of radiotherapy, no negative impact on neurological function
was observed [12, 13, 19]. Brown et al. [20] concluded, based on
literature review, that the weight of evidence suggests only
sporadic, limited neurocognitive damage from focal
radiotherapy at the usually prescribed doses for LGG.
Focal or conformal delivery of radiotherapy to the tumour
while sparing surrounding normal tissues is the most important
goal and can be achieved with modern radiotherapy techniques.
New techniques like stereotactic radiotherapy, intensity
modulated radiotherapy (IMRT), image guided radiotherapy or
proton therapy are characterized by a high level of accuracy in
the delivery of radiation to tumour tissue leading to
a substantial improvement of treatment results.
It has been demonstrated that the use of computed
tomography-based full three-dimensional (3D) treatment
planning techniques compared with simple 3D planning
techniques in patients with an astrocytoma results in a 30%
reduction in the volume of brain tissue treated to a high dose
level (>95% isodose line) [21]. Furthermore, a 50% reduction
of normal brain irradiated is observed [21]. As a consequence,
there is less intellectual impairment in long-term survivors
[22]. Sparing of normal tissue has recently been further
developed by the use of IMRT resulting in conformal avoidance
of normal brain tissue, for example the hippocampal area
which is hypothesized to the risk of memory function decline.
This specific hypothesis focused on sparing the migrating stem
cell compartment in the hippocampus responsible for post-
radiotherapy neurogenesis as a component of preserving
memory function and was shown to be feasible by the use of
IMRT [23].
It can therefore be reasonably assumed that a high level of
dose conformity will improve the efficacy of treatment by
decreasing normal tissue toxicity and contribute to more
specific sparing of defined areas at high risk for neurocognitive
toxicity.
chemotherapy
Adjuvant chemotherapy after radiation has been explored in
a large randomized RTOG trial (#9802). High-risk patients
were randomized to postoperative radiotherapy with or
without subsequent adjuvant PCV chemotherapy. After
stratification by age, histology, KPS and presence/absence of
contrast enhancement on preoperative MRI patients were
randomized to either radiotherapy alone (54 Gy) (Arm 2) or
radiotherapy followed by six cycles of standard dose PCV (Arm
3). The initial analysis after a median follow-up of >4 years did
not show an advantage for the administration of chemotherapy,
even in the group of high-risk LGG [9].
chemotherapy for recurrent LGG
At recurrence after prior radiotherapy LGG will often have
transformed into a higher malignant grade. Repeat surgery may
be indicated when feasible; however, often these patients are
considered for chemotherapy without repeat histological
confirmation of the tumour grade. Thus, reported efficacy for
recurrent low-grade tumour includes variable histologies and
grades, often determined by surgery or biopsy years earlier.
In general, objective response rates to currently available
chemotherapy have been modest ([24, 25] and Table 4).
Temozolomide, a novel alkylating agent, has demonstrated
activity in the treatment of recurrent high-grade glioma. Recent
studies have also suggested some activity in LGG.
response rates
Response to treatment and prognosis may vary markedly in
LGG. The natural history of oligodendroglial tumours is more
protracted compared with astrocytic tumours. Furthermore,
oligodendrogliomas show a higher sensitivity to chemotherapy.
In particular pure oligodendroglioma with a loss of
heterozygosity on chromosomes 1p/19q (recently identified as
a translocation) has been identified as a distinct entity with
a much more favourable natural history irrespective of
treatment, and a particular responsiveness to chemotherapy
and most likely also to radiotherapy [31]. Response rates after
PCV or temozolomide (TMZ) chemotherapy as high as 90–
100% have been reported for recurrent (and transformed–
anaplastic) oligodendroglioma [30, 32, 33] but were also shown
in non-pretreated patients [34].
The standard chemotherapy regimen [PCV regimen,
procarbazine, lomustine (CCNU) and vincristine] is often
Table 3. Randomized studies of radiotherapy for LGG
Study Histology Treatment arm No. 5-year survival P value
OS (%) PFS (%) OS (%) PFS (%)
Timing of radiotherapy
EORTC 22845 [8] AA, OD, OA S 157 66 35 NS <0.0001
S + RT 157 68 55
Dose of radiotherapy
EORTC 22844 [5] AA, OD, OA, PA S + RT 45 Gy 171 58 47 NS NS
S + RT 59.4 Gy 172 59 50
NCCTG-RTOG-ECOG [3] AA, OD, OA S + RT 50.4 Gy 102 73 55 NS
S + RT 64.8 Gy 103 68 52
Abbreviations: AA, astrocytoma; OD, oligodendroglioma; OA, oligoastrocytoma; PA, pilocytic astrocytoma; S, surgery; RT, radiotherapy; Gy, Gray; NS, not
significant.
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replaced by single-agent TMZ chemotherapy. Although TMZ
has never been formally compared with PCV, TMZ is
commonly favoured for its ease of administration and
favourable toxicity profile. Cumulative myelosuppression,
fatigue and weight loss frequently cause prolonged treatment
intervals or even discontinuation of PCV chemotherapy. TMZ
is given orally and is usually well tolerated even when
administered for a prolonged time (1–2 years). Severe
toxicity, namely thrombocytopenia, lymphopenia and
neutropenia as well as nausea and fatigue are observed in
<10% of patients.
chemotherapy with TMZ
The recent EORTC study 26971 on first-line TMZ
chemotherapy in recurrent oligodendroglioma has shown
a response rate of just over 50% to this agent [38] Alternatively,
dose-intense continuous dosing schedules have been
Table 4. Chemotherapy for recurrent LGG
Author No. Prior therapy Therapy Response Survival (months)
Van den Bent 1998 [26] 52 OD + OA RT 100% PCV OD: 9/20 (45%); OA:
33%; RR 64%
MTP: 8
Soffietti 1998 [27] 26 17 OD, 9 OA RT 42%; CT 0% PCV 12% CR, 50% PR; RR 62% MTP: 24
Van den Bent 2003 [28] 32, elig. 28 17
OD, 11 OA
RT 100%; CT 100% TMZ 7 PR; RR 25% MOS: 12.3
Pace 2003 [29] 43 29 AA, 10
OA, 4 OD
RT 70%; CT 37% TMZ 4 CR, 16 PR, 17 SD, 6 PD 6-month PFS 76.8%; 12-month
PFS 39.6%; MTP: 10
Levin 2006 [30] 28 OD RT 0%; CT 0% TMZ 10 PR, 7 MR, 10 SD,
1 PD; RR 61%
12-month PFS 89%, 24-month
PFS 70%; MTP: 31
Abbreviations: AA, astrocytoma; OD, oligodendroglioma; OA, oligoastrocytoma; PA, pilocytic astrocytoma; CR, complete response; PR, partial response; RR,
response rate; MTP, median time to progression; MOS, median overall survival; RT, radiotherapy: CT, chemotherapy.
Table 5. Neo-adjuvant chemotherapy for patients with LGG
Author No. Response Therapy Toxicity Histology
Mason 1996 [34] 9 6 PR, 3 SD (2 MR) PCV/I-PCV I-PC: high
Soffietti 1999 [35] 13 3 PR, 10 SD (2 MR), 2/5 improved symptoms PCV low OD, OA
Mason 2001 [36] 8 2 PR, 5/6 symptoms improved Mini-PCV moderate 6 OD, 2 OA
Buckner 2003 [37] 28 8 PR, 17 SD, 3 PD PCV moderate 17 OD, 11 OA
Abbreviations: AA, astrocytoma; OD, oligodendroglioma; OA, oligoastrocytoma; PA, pilocytic astrocytoma; CR, complete response; PR, partial response; SD,
stable disease; MR, minimal response; PD, progressive disease.
Table 6. Temozolomide as primary therapy in LGG
Author No. Treatment Response Survival Toxicity
Brada 2003 [42] 29: 10 OD,
17 AA, 2 OA
200 mg/m2 ·
5/28 days
10% PR, 48% MR, 38%
SD, 1 patient PD, 17/18
improved symptoms
36-month PFS: 66%;
36-month OS 82%
low
Quinn 2003 [43] 46 (14 prior tx);
20 OD, 5 OA,
5 piloc. 16 AA
200 mg/m2 ·
5/28 days
CR 11, PR 17,
SD 16; RR 61%
Med. PFS 22 months;
12-month PFS 76%
low
Hoang-Xuan
2004 [32]
60: 49 OD, 11 OA 200 mg/m2 ·
5/28 days
7% PR, 14% MR, 61% S
D, 8% PD; RR 31%
12-month PFS 73%.
Med. time to max
response 12 months
8% grade 3–4
(myelosuppression)
Pouratian 2007 [44] 25 75 mg/m2 ·
21/28 days
RR 52% (CR, PR and MR).
Disease control rate 84%
(CR, PR, MR and SD)
CR, PR, MR and SD)
6-month PFS 92%,
12-month PFS 72%
48% grade 3 (mostly
lymphopenia, 1 neurocognitive),
1 grade 4 (sec. malignancy)
Abbreviations: AA, astrocytoma; OD, oligodendroglioma; OA, oligoastrocytoma; PA, pilocytic astrocytoma; CR, complete
response; PR, partial response; SD, stable disease; MR, minimal response; PD, progressive disease.
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investigated [39, 40] and two studies have shown the feasibility
of a continuous dosing schedule. In a 21 days on/7 days off
schedule patients can be treated with 85–100 mg/m2 daily with
double the dose intensity compared with the standard 5-day
regimen [41]. As low-grade tumours have a limited number of
cells in the proliferation phase the investigation of a drug in
a more continuous administration is theoretically attractive.
Furthermore, increased response is expected by the depletion of
the intra-tumour methyl-guanine alkyl-transferase (MGMT),
a DNA repair enzyme that is consumed by chronic alkylating
agent chemotherapy.
conclusion
Treatment of LGG is still challenging and is based mainly on
the best definition of prognostic factors, also due to the lack of
randomized controlled studies. From one randomized trial we
may conclude that watchful waiting remains a valid option for
patients with LGG without risk factors. For patients at risk for
rapidly progressive disease and malignant transformation, the
optimal treatment has yet to be defined. Higher doses of
radiation (>45–50 Gy) have failed to demonstrate an improved
outcome and are associated with increased late toxicity, notably
neurocognitive deterioration and radiation necrosis. Adjuvant
chemotherapy (PCV) after radiation did not translate into
improved outcome in high-risk patients in a preliminary
analysis with a median follow-up of 4 years.
A number of phase II studies have demonstrated anti-
tumour activity of TMZ in LGG, both in the recurrent setting
and as primary therapy. In particular oligodendroglioma with
loss of heterozygosity 1p/19q has been identified as a distinct
pathological entity with much more favourable prognosis and
responsiveness to both chemotherapy and irradiation. Often
these patients are considered for primary therapy with TMZ,
although the available evidence does not support this approach.
On an individual basis radiotherapy for smaller and localized
tumours may be more appropriate, simpler, less toxic and less
costly than prolonged chemotherapy over many months, while
for large tumours requiring extended radiation fields primary
chemotherapy may be considered.
In an ongoing international Intergroup study [EORTC
22033–26033, National Cancer Institute of Canada (NCIC)
Clinical Trials Group study CE.5; Tasmanian Radiation
Oncology Group (TROG), Australia] patients with high-risk
disease or with progressive tumours are randomized between
primary radiotherapy (28 · 1.8 Gy, 50.4 Gy, control arm) or
primary chemotherapy with low-dose TMZ for up to 1 year (12
cycles) (Figure 1). In addition to clinical factors patients are
stratified according to a molecular analysis of the 1p/19q status.
The central collection of tissue will also allow subsequent
identification of additional molecular markers in order to
predict individual outcome and response to therapy. Trial
endpoints are progression-free survival, overall survival, but
also acute and delayed toxicity, quality of life and cognitive
function
Novel techniques allow the delivery of highly conformal
radiotherapy with minimal toxicity to the normal brain. In the
future radiotherapy based on modern imaging as co-registered
MRI and positron emission tomography (PET) scans will limit
the amount of normal tissue irradiated without compromising
tumour control.
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